Skip to main content
Fig. 4 | Journal of Nanobiotechnology

Fig. 4

From: Recent advances in porous nanomaterials-based drug delivery systems for cancer immunotherapy

Fig. 4

(Adapted with permission from [61]. Copyright © 2019 American Chemical Society)

Inorganic porous nanomaterials for tumor immunotherapy. A Schematic illustration of synthesis of bMSN (CpG/Ce6)-neoantigen and mechanism of the composite as nanovaccines for PDT-mediated immunotherapy. B Serial PET images of MC-38 tumor-bearing mice at different time points postinjection of 64Cu-NOTA-Adpgk or 64Cu-NOTA-bMSN (CpG/Ce6)-Adpgk. Tumors are indicated by yellow arrowheads. C Biodistribution of 64Cu-NOTA-Adpgk and 64Cu-NOTA-bMSN (CpG/Ce6)-Adpgk in MC-38 tumor-bearing mice at 25 h postinjection. D Overall survival curves of each group. E Average primary and contralateral tumor growth curves of each group. F On day 21, IFN-γ ELISPOT assay was conducted by ex vivo restimulation of splenocytes with M27 and M30 peptides at a concentration of 10 μg/ml. Meanwhile, tumor tissues were analyzed for the frequencies of CD3+CD8α+ T-cells (G) and CD11c+CD86+ DCs (H) by flow cytometry

Back to article page